Benefits of a comprehensive care model in patients with heart failure and chronic obstructive pulmonary disease: UMIPIC Program.

M Méndez Bailón, Á González-Franco, J M Cerqueiro, J Pérez-Silvestre, C Moreno García, A Conde-Martel, J C Arévalo-Lorido, F Formiga Pérez, L Manzano-Espinosa, M Montero-Pérez-Barquero
{"title":"Benefits of a comprehensive care model in patients with heart failure and chronic obstructive pulmonary disease: UMIPIC Program.","authors":"M Méndez Bailón, Á González-Franco, J M Cerqueiro, J Pérez-Silvestre, C Moreno García, A Conde-Martel, J C Arévalo-Lorido, F Formiga Pérez, L Manzano-Espinosa, M Montero-Pérez-Barquero","doi":"10.1016/j.rceng.2024.10.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with heart failure (HF) and chronic obstructive pulmonary disease (COPD) have a high risk of hospital admission and mortality. This study evaluated the benefit of a care model, characterized by comprehensive and continuous care (UMIPIC program) in patients with HF and a history of COPD.</p><p><strong>Methods: </strong>A total of 5644 patients were prospectively recruited, of which 1320 had a history of COPD between March 2008 and March 2020. They were divided into 2 follow-up groups at the time of discharge, one in follow-up in the UMIPIC program (435 patients) and another treated conventionally (885 patients). The baseline characteristics of each group were analyzed and patients in each group were selected by propensity score matching and admissions and mortality were evaluated during 12 months of follow-up, after an episode of hospitalization for HF.</p><p><strong>Results: </strong>The UMIPIC group, compared to the conventional group in the matched cohort, had a lower rate of admissions for HF (21% vs 30 respectively; hazard ratio [HR] = 0.64; 95% confidence interval [95% CI]: 0.54-0.84; p = 0.002) and mortality (28% vs 36%, respectively; HR = 0.68; 95% CI: 0.51-0.90; p = 0.008). From a therapeutic point of view, patients with HF and a history of COPD who were followed in the UMIPIC program received a higher percentage of beta-blockers (64% vs 54%; p < 0.05) and direct-acting anticoagulants (17% vs 9%: p < 0.05) than those followed conventionally.</p><p><strong>Conclusions: </strong>The implementation of the UMIPIC care program for patients with HF and a history of COPD, based on comprehensive and continuous care, reduces both admissions and mortality at one year of follow-up. The prescription of beta-blockers and direct-acting anticoagulants was also higher during follow-up in the UMIPIC program.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista clinica espanola","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.rceng.2024.10.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients with heart failure (HF) and chronic obstructive pulmonary disease (COPD) have a high risk of hospital admission and mortality. This study evaluated the benefit of a care model, characterized by comprehensive and continuous care (UMIPIC program) in patients with HF and a history of COPD.

Methods: A total of 5644 patients were prospectively recruited, of which 1320 had a history of COPD between March 2008 and March 2020. They were divided into 2 follow-up groups at the time of discharge, one in follow-up in the UMIPIC program (435 patients) and another treated conventionally (885 patients). The baseline characteristics of each group were analyzed and patients in each group were selected by propensity score matching and admissions and mortality were evaluated during 12 months of follow-up, after an episode of hospitalization for HF.

Results: The UMIPIC group, compared to the conventional group in the matched cohort, had a lower rate of admissions for HF (21% vs 30 respectively; hazard ratio [HR] = 0.64; 95% confidence interval [95% CI]: 0.54-0.84; p = 0.002) and mortality (28% vs 36%, respectively; HR = 0.68; 95% CI: 0.51-0.90; p = 0.008). From a therapeutic point of view, patients with HF and a history of COPD who were followed in the UMIPIC program received a higher percentage of beta-blockers (64% vs 54%; p < 0.05) and direct-acting anticoagulants (17% vs 9%: p < 0.05) than those followed conventionally.

Conclusions: The implementation of the UMIPIC care program for patients with HF and a history of COPD, based on comprehensive and continuous care, reduces both admissions and mortality at one year of follow-up. The prescription of beta-blockers and direct-acting anticoagulants was also higher during follow-up in the UMIPIC program.

综合护理模式对心力衰竭和慢性阻塞性肺病患者的益处:UMIPIC 计划。
背景:心力衰竭(HF)和慢性阻塞性肺疾病(COPD)患者的入院风险和死亡率都很高。这项研究评估了以全面持续护理为特点的护理模式(UMIPIC 计划)对心力衰竭合并慢性阻塞性肺病患者的益处:方法:2008 年 3 月至 2020 年 3 月期间,共前瞻性招募了 5644 名患者,其中 1320 人有慢性阻塞性肺病病史。他们在出院时被分为两个随访组,一个是UMIPIC项目随访组(435名患者),另一个是常规治疗组(885名患者)。对每组患者的基线特征进行分析,并通过倾向得分匹配法选出每组患者,在因高血压住院治疗后的12个月随访期间对入院情况和死亡率进行评估:结果:与匹配队列中的传统组相比,UMIPIC 组的心房颤动入院率较低(分别为 21% vs 30;危险比 [HR] = 0.64;95% 置信区间 [95% CI]:0.54-0.84;P<0.05):0.54-0.84; p = 0.002)和死亡率(分别为 28% vs. 36%; HR = 0.68; 95% CI: 0.51-0.90; p = 0.008)。从治疗角度来看,接受UMIPIC项目随访的患有心房颤动和慢性阻塞性肺病的患者接受β-受体阻滞剂治疗的比例更高(64% 对 54%;P 结论:UMIPIC项目的实施对心房颤动和慢性阻塞性肺病患者的治疗效果更好:对患有心房颤动且有慢性阻塞性肺病史的患者实施 UMIPIC 护理计划,以全面、持续的护理为基础,可减少随访一年后的入院率和死亡率。在 UMIPIC 项目的随访期间,β-受体阻滞剂和直接作用抗凝剂的处方量也有所增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信